Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Amendment No. 3 to a Schedule 13D reports that Samsara-affiliated entities and Dr. Srinivas Akkaraju collectively beneficially own 6,346,194 shares of Mineralys Therapeutics, Inc. common stock, representing 8.2% of the class. The filing discloses that on September 4, 2025, Samsara Opportunity Fund, L.P. purchased 588,235 shares at $25.50 per share in the issuer's public offering for an aggregate price of $14,999,993, funded by short-term borrowing from Samsara BioCapital, L.P. Ownership breakouts include 5,674,916 shares held by Samsara BioCapital, L.P. (7.3%) and 588,235 held by Samsara Opportunity Fund, L.P. (0.8%), with Dr. Akkaraju holding vested and near-vesting options that are included in his 8.2% figure. A 60-day lock-up from September 2, 2025 applies to directors and officers, including Dr. Akkaraju.
RA Capital and related persons report ownership of 7,796,433 shares of Mineralys Therapeutics (MLYS), representing 9.9% of the company on a stated basis. The filing amends prior Schedule 13D disclosures to reflect that on September 4, 2025 the RA Capital Healthcare Fund, L.P. purchased 1,176,470 shares in the issuer's September 2025 public offering at $25.50 per share for an aggregate $29,999,985 funded from the Fund's working capital. The reporting persons disclose 5,456,521 shares held directly by the Fund, 1,867,229 shares held by RA Capital Nexus Fund III, vested and soon-to-vest employee options, and Pre-Funded Warrants subject to a "Beneficial Ownership Blocker" that prevents exercise above 9.99% ownership. RA Capital serves as investment adviser and has sole voting and dispositive power for the Fund and Nexus Fund III, though the Fund and Nexus Fund III disclaim beneficial ownership for Section 13(d) purposes due to delegation of those powers.
RA Capital entities reported an acquisition of Mineralys Therapeutics (MLYS) common stock on 09/04/2025. The filing shows a purchase of 1,176,470 shares at $25.50 per share. After the transaction, the reporting persons disclosed 5,456,521 shares beneficially owned (indirect) and an additional line showing 1,867,229 shares beneficially owned (indirect), with holdings held directly by RA Capital Healthcare Fund, L.P. and Nexus Fund III, L.P. The filing identifies RA Capital Management, L.P. as adviser and names Dr. Peter Kolchinsky and Rajeev Shah among reporting individuals; a partner of the adviser, Dr. Derek DiRocco, serves on the issuer's board. The form is signed by the reporting persons on 09/08/2025.
Mineralys Therapeutics entered into an underwriting agreement to sell 9,803,921 shares of common stock at a public offering price of $25.50 per share, with the underwriters purchasing the shares from the company at $23.97 per share. The company expects net proceeds of approximately $234.7 million, or about $269.9 million if the underwriters' 30-day option to buy an additional 1,470,588 shares is exercised in full. The offering is expected to close on September 4, 2025, subject to customary closing conditions.
The transaction is being conducted under previously declared Form S-3 registration statements and is accompanied by customary representations, indemnities and closing conditions. The filing includes the underwriting agreement and counsel opinion as exhibits. The company also included a forward-looking statements caution noting that actual results may differ due to market conditions and closing risks.
Mineralys Therapeutics (MLYS) is offering securities under a $500,000,000 registration, including resale registration for 8,888,924 shares related to a $120.0 million private placement completed at $13.50 per share (including pre-funded warrants). The company is an emerging growth and smaller reporting company and its common stock trades on Nasdaq under MLYS (last reported price $12.69 on March 15, 2024). An underwriter option allows purchase of up to 1,470,588 additional shares for 30 days. Mineralys is a clinical-stage biopharma developing lorundrostat, an oral aldosterone synthase inhibitor; a Phase 2 proof-of-concept trial in 200 subjects reported a clinically meaningful, statistically significant blood-pressure reduction with once-daily dosing and good tolerability. The prospectus discloses broad use-of-proceeds discretion, a 60-day lock-up for insiders, extensive international selling restrictions, and tax and dividend treatment details for non-U.S. holders.
Mineralys Therapeutics, Inc. reported that on September 2, 2025 it delivered written notice to BofA Securities and Evercore Group suspending its use of, and terminating, the April 11, 2024 prospectus supplement for its at-the-market (ATM) equity offering program. This prospectus supplement had covered sales of common stock under the ATM Equity Offering Sales Agreement dated March 21, 2024.
The company stated it will not make any sales of common stock under the Sales Agreement unless and until a new prospectus supplement is filed with the SEC. The underlying Sales Agreement with BofA Securities and Evercore remains in full force and effect.
Mineralys Therapeutics (MLYS) is offering $175,000,000 of common stock and has an existing shelf registration to offer up to $500,000,000 of various securities, including common stock, preferred stock, debt securities, warrants and units. The prospectus registers resale of up to 8,888,924 shares by selling stockholders; Mineralys will not receive proceeds from those resales. The company previously completed a private placement for aggregate gross proceeds of approximately $120.0 million consisting of 8,339,169 shares at $13.50 and 549,755 pre-funded warrants.
Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor initially for uncontrolled and resistant hypertension and cardiorenal conditions. In a Phase 2 proof-of-concept trial (Target-HTN, 200 subjects) lorundrostat produced a clinically meaningful, statistically significant blood pressure reduction and was well tolerated. The filing emphasizes high investment risk and discloses Nasdaq listing (MLYS) and recent prices of $12.69 (Mar 15, 2024) and $15.48 (Aug 29, 2025).
Mineralys Therapeutics insider activity: Dr. David Malcom Rodman, the company's Chief Medical Officer, exercised options and sold common stock under a Rule 10b5-1 plan. On 08/12/2025 he exercised stock options to acquire 6,349 shares at an exercise price of $1.08, increasing his direct beneficial ownership to 104,256 shares. The related option grants vesting details are stated: 25% vested on 07/12/2022 with the remainder vesting in 36 monthly installments. On 08/13/2025 he sold 11,365 shares at a weighted-average price of $12.9333, with sale prices ranging from $12.590 to $13.223. The transactions were effected pursuant to a 10b5-1 trading plan adopted on 10/25/2024.
Mineralys Therapeutics (MLYS) Schedule 13G/A reports that BioDiscovery 6 FPCI, Andera Partners and two Andera managing partners, Stephane Bergez and Francois Xavier Mauron, together may be deemed to beneficially own 2,765,976 shares of common stock, representing 4.2% of the class based on 65,175,287 shares outstanding as of May 8, 2025. The shares are held of record by BioDiscovery 6; voting and dispositive authority is shared (no sole voting or dispositive power reported). The filers disclaim status as a group. The filing discloses Paris as the reporting persons' principal address and includes a joint filing agreement as an exhibit.
Catalys Pacific entities and an individual reported shared beneficial ownership of 8,978,954 shares, representing 13.5% of Mineralys Therapeutics, Inc. The filing states this total includes 8,903,838 shares held of record by Catalys Pacific Fund, LP and 75,116 shares underlying options exercisable within 60 days of June 30, 2025. The reporting group consists of Catalys Pacific Fund, LP; Catalys Pacific Fund GP, LP; Catalys Pacific, LLC; and Brian Taylor Slingsby, who is the managing director and signed the filing on August 14, 2025. Ownership figures are based on 66,295,184 shares outstanding as disclosed by the issuer.